Oxford Pharmascience’s 2015 results highlight the significant potential of its NSAID pipeline. The group has recently entered early stage partnering discussions for both OXPzeroTM Ibuprofen and OXPzeroTM Naproxen and is encouraged by the strong level of interest from major players in this space. The £20m equity capital raise undertaken during the period should enable to the group to negotiate commercialisation deals from a position of strength whilst it continues to progress development of its p ....
